Browse by author
Lookup NU author(s): Leon Pybus,
Professor Jarka Glassey
This is the authors' accepted manuscript of an article that has been published in its final definitive form by Wiley - V C H Verlag GmbH & Co. KGaA, 2019.
For re-use rights please refer to the publisher's terms and conditions.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim High-Throughput (HT) technologies such as miniature bioreactors (MBRs) are increasingly employed within the biopharmaceutical manufacturing industry. Traditionally, these technologies have been utilized for discrete screening approaches during pre-clinical development (e.g., cell line selection and process optimization). However, increasing interest is focused towards their use during late clinical phase process characterization studies as a scale-down model (SDM) of the cGMP manufacturing process. In this review, the authors describe a systematic approach toward SDM development in one of the most widely adopted MBRs, the ambr 15 and 250 mL (Sartorius Stedim Biotech) systems. Recent efforts have shown promise in qualifying ambr systems as SDMs to support more efficient, robust and safe biomanufacturing processes. The authors suggest that combinatorial improvements in process understanding (matching of mass transfer and cellular stress between scales through computational fluid dynamics and in vitro analysis), experimental design (advanced risk assessment and statistical design of experiments), and data analysis (combining uni- and multi-variate techniques) will ultimately yield ambr SDMs applicable for future regulatory submissions.
Author(s): Sandner V, Pybus LP, McCreath G, Glassey J
Publication type: Article
Publication status: Published
Journal: Biotechnology Journal
Print publication date: 01/04/2019
Online publication date: 23/10/2018
Acceptance date: 02/04/2018
Date deposited: 25/11/2019
ISSN (print): 1860-6768
ISSN (electronic): 1860-7314
Publisher: Wiley - V C H Verlag GmbH & Co. KGaA
Altmetrics provided by Altmetric